Two Omicron subvariants continued to slowly spread in the United States, almost completely edging out BA.2, which became dominant in the spring, the Centers for Disease Control and Prevention (CDC) said today in its latest update.In other developments, Pfizer and BioNTech updated their efficacy estimates for the COVID-19 vaccine for children aged 6 months to 4 years.Omicron subvariants push out BA.2BA.5 now accounts for 88.9% of sequenced samples, up slightly from 88% the previous week.
Also, BA.4.6, which first gained traction in the central Midwest, gained more ground and now accounts for 6.3% of sequenced samples, up from 5.3% the week before.The central midwestern states, which include Iowa, Kansas, Missouri, and Nebraska, were the first to see growing proportions of BA.4.6 and are still seeing the highest percentage, with the subvariant making up nearly 16% of samples.
However, the proportions of the subvariant are higher than the national average in eastern and southeastern states.As school resumes in some parts of the country, the trend with pediatric COVID-19 infections continues to fluctuate, as has the pattern for the general US population over the summer.
In its latest weekly update, the American Academy of Pediatrics (AAP) said nearly 80,000 infections in kids were reported over the past week, down for the second week in a row.The nation's 7-day average for new daily cases continues to fall slowly and is at 92,602, the lowest since mid-May, according to the New York Times tracker.